Coherex Medical has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.
Coherex Medical has expanded its product portfolio with the unveiling of its Coherex WaveCrest LAA Occluder System, a new medical device designed to safely and easily close the Left Atrial Appendage (LAA).
Coherex WaveCrest LAA Occluder System successfully used for the first time in a human, performed at Auckland City Hospital in New Zealand.
Coherex said that the WaveCrest presents a valuable new treatment option for patients who suffer from atrial fibrillation and the associated risks of stroke, and possibly enables patients to discontinue difficult-to-manage blood thinners such as Coumadin (Warfarin).
Coherex Medical president and CEO Richard Linder said that the results of the procedure represent many years of intensive product development and testing.
“We are very excited about the potential of our LAA closure program, as the Coherex WaveCrest performed to our highest expectations in this first case in man,” Linder said.